- Home
- PAVM vs CERO Comparison
PAVM vs CERO Comparison
Compare PAVM & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- CERO
- Stock Information
- Founded
- PAVM 2014
- CERO 2017
- Country
- PAVM United States
- CERO United States
- Employees
- PAVM N/A
- CERO N/A
- Industry
- PAVM Medical/Dental Instruments
- CERO
- Sector
- PAVM Health Care
- CERO
- Exchange
- PAVM Nasdaq
- CERO Nasdaq
- Market Cap
- PAVM 12.0M
- CERO 3.5M
- IPO Year
- PAVM 2016
- CERO N/A
- Fundamental
- Price
- PAVM $0.56
- CERO $8.70
- Analyst Decision
- PAVM Strong Buy
- CERO Strong Buy
- Analyst Count
- PAVM 1
- CERO 2
- Target Price
- PAVM $19.00
- CERO $45.00
- AVG Volume (30 Days)
- PAVM 151.6K
- CERO 3.3M
- Earning Date
- PAVM 08-11-2025
- CERO 08-13-2025
- Dividend Yield
- PAVM N/A
- CERO N/A
- EPS Growth
- PAVM N/A
- CERO N/A
- EPS
- PAVM 0.96
- CERO N/A
- Revenue
- PAVM $1,993,000.00
- CERO N/A
- Revenue This Year
- PAVM N/A
- CERO N/A
- Revenue Next Year
- PAVM $455.63
- CERO N/A
- P/E Ratio
- PAVM $0.58
- CERO N/A
- Revenue Growth
- PAVM N/A
- CERO N/A
- 52 Week Low
- PAVM $0.55
- CERO $6.71
- 52 Week High
- PAVM $1.90
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- PAVM 36.29
- CERO 46.62
- Support Level
- PAVM $0.55
- CERO $9.10
- Resistance Level
- PAVM $0.61
- CERO $9.73
- Average True Range (ATR)
- PAVM 0.03
- CERO 1.50
- MACD
- PAVM -0.00
- CERO -0.01
- Stochastic Oscillator
- PAVM 4.47
- CERO 10.78
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.